COMP <GO>
GMED vs ABBV // GROSS PROFIT MARGIN
Globus Medical Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: GMED 8
— ABBV 7
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $78.05 (-5.86%) • MKT CAP: $11.13B
gross-margins
67.40%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 67.40% | 70.20% | -2.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 29.00% | -20.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 33.3x | -15.70 | GMED | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 3.47% | +1.82 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | 24.60% | -8.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 6.90% | +11.40 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 8.60% | +8.10 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 5.33 | +5.41 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | GMED | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 72.8 | -23.75 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.15 | -0.08 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 113.1x | -95.70 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $513.86B | -$502.73B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | ABBV REV | GMED GROSS % | ABBV GROSS % | GMED FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $61.16B | 67.4% | 70.2% | $588.8M | $17.82B |
| FY 2024 | $2.52B | $56.33B | 58.9% | 70.0% | $405.2M | $17.83B |
| FY 2023 | $1.57B | $54.32B | 44.0% | 44.0% | $172.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
ABBV // BETA 1.15